Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Amortizatization of Intangibles: 2019-2024

Historic Amortizatization of Intangibles for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $6.4 million.

  • C4 Therapeutics' Amortizatization of Intangibles rose 4.58% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 4.45%. This contributed to the annual value of $6.4 million for FY2024, which is 4.25% up from last year.
  • Per C4 Therapeutics' latest filing, its Amortizatization of Intangibles stood at $6.4 million for FY2024, which was up 4.25% from $6.2 million recorded in FY2023.
  • Over the past 5 years, C4 Therapeutics' Amortizatization of Intangibles peaked at $6.4 million during FY2024, and registered a low of -$1.9 million during FY2021.
  • For the 3-year period, C4 Therapeutics' Amortizatization of Intangibles averaged around $6.2 million, with its median value being $6.2 million (2023).
  • Per our database at Business Quant, C4 Therapeutics' Amortizatization of Intangibles crashed by 253.51% in 2021 and then skyrocketed by 413.78% in 2022.
  • Over the past 5 years, C4 Therapeutics' Amortizatization of Intangibles (Yearly) stood at $1.2 million in 2020, then tumbled by 253.51% to -$1.9 million in 2021, then surged by 413.78% to $5.9 million in 2022, then rose by 4.46% to $6.2 million in 2023, then rose by 4.25% to $6.4 million in 2024.